Recursion Pharmaceuticals, Inc. last reported quarterly results on Oct 15, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $18.6 million (+258.5% year over year) and diluted EPS of -$0.22. It usually reports 15–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 24, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 25, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 15–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 15, 2026
15 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
19
+258.5%
|
-119
+26.6%
|
-0.22
+38.9%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
8
-60.1%
|
-131
+23.8%
|
-0.25
+39.0%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
6
-56.1%
|
-118
+42.0%
|
-0.22
+56.0%
|
|
Feb 25, 2026
56 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
36
+681.7%
|
-108
+39.6%
|
-0.21
+61.0%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
5
-80.2%
|
-162
-69.3%
|
-0.36
-5.9%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
19
+33.3%
|
-172
-76.2%
|
-0.41
-2.5%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
15
+6.9%
|
-202
-121.6%
|
-0.50
-28.2%
|
|
Feb 28, 2025
59 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
5
-58.3%
|
-179
-92.4%
|
-0.53
-27.1%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1601830
- Former names
- Recursion Pharmaceuticals, LLC (until Dec 4, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.